Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Oligodendrocytes readily regenerate and replace myelin membranes around axons in the adult mammalian central nervous system (CNS) following injury. The ability to regenerate oligodendrocytes depends on the availability of neural progenitors called oligodendrocyte precursor cells (OPCs) in the adult CNS that respond to injury-associated signals to induce OPC expansion followed by oligodendrocyte differentiation, axonal contact and myelin regeneration (remyelination). Remyelination ensures the maintenance of axonal conduction, and the oligodendrocytes themselves provide metabolic factors that are necessary to maintain neuronal integrity. Recent advances in oligodendrocyte regeneration research are beginning to shed light on critical intrinsic signals, as well as extrinsic, environmental factors that regulate the distinct steps of oligodendrocyte lineage progression and myelin replacement under CNS injury. These studies may offer novel pharmacological targets for regenerative medicine in inflammatory demyelinating disorders in the CNS such as multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Molecular dissection of reactive astrogliosis and glial scar formation
Sofroniew, M. V. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.08.002 · Cited by 2,594 · cited 3×
“LIF, IGF1, PDGFalpha, CNTF) (Sofroniew, 2009).”
BackgroundInfluentialMacrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664 · cited 3×
“In addition to increasing axonal conduction speed through generating myelin, oligodendrocytes secrete metabolic factors that maintain the integrity and survival of CNS neurons (Edgar et al., 2009; Fünfschilling et al., 2012; Griffiths et al., 1998; Lee et al., 2012; Oluich et al., 2012).”
BackgroundRemyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544 · cited 1×
“One of the most intriguing features of the adult CNS is its ability to spontaneously regenerate oligodendrocytes and replace myelin (remyelination) following acute demyelination (Franklin and Ffrench-Constant, 2008).”
BackgroundInfluentialAxonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Fünfschilling, U., Supplie, L. M., Mahad, D., Boretius, S., Saab, A. S., Edgar, J., Brinkmann, B. G., Kassmann, C. M., Tzvetanova, I. D., Möbius, W., et al. (2012) · Nature · doi:10.1038/nature11007 · Cited by 1,523 · cited 2×
“In addition to increasing axonal conduction speed through generating myelin, oligodendrocytes secrete metabolic factors that maintain the integrity and survival of CNS neurons (Edgar et al., 2009; Fünfschilling et al., 2012; Griffiths et al., 1998; Lee et al., 2012; Oluich et al., 2012).”
BackgroundDisruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 6×
“Semaphorin Signaling: Failure of OPCs to migrate into demyelinated lesions may contribute to failed remyelination in approximately 30% of MS lesions which exhibit reduced OPC numbers (Chang et al., 2002; Lucchinetti et al., 1999).”
BackgroundInfluentialDawson, M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00210-0 · Cited by 927 · cited 1×
“Oligodendrocyte regeneration is possible because of an abundantly distributed source of oligodendrocyte precursor cells (OPCs) in the adult CNS (Dawson et al., 2003; Horner et al., 2002; Pringle et al., 1992; van Wijngaarden and Franklin, 2013).”
BackgroundA critical period for social experience-dependent oligodendrocyte maturation and myelination
Makinodan, M., Rosen, K. M., Ito, S., & Corfas, G. (2012) · Science · doi:10.1126/science.1220845 · Cited by 922 · cited 2×
“, 2005), ErbB3 may mediate experience-dependent myelination (Makinodan et al., 2012).”
BackgroundAcute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 1×
“APP accumulation is present in active, remyelinating, and inactive MS lesions (Bitsch et al., 2000; Ferguson et al., 1997).”
BackgroundAxonal Swellings and Degeneration in Mice Lacking the Major Proteolipid of Myelin
Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M. H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N., et al. (1998) · Science · doi:10.1126/science.280.5369.1610 · Cited by 889 · cited 2×
“In addition to increasing axonal conduction speed through generating myelin, oligodendrocytes secrete metabolic factors that maintain the integrity and survival of CNS neurons (Edgar et al., 2009; Fünfschilling et al., 2012; Griffiths et al., 1998; Lee et al., 2012; Oluich et al., 2012).”
BackgroundKuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Myelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
Argaw, A. T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J. N., Mahase, S., Dutta, D. J., Seto, J., Kramer, E. G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60842 · Cited by 733 · cited 2×
“Reactive astrocytes also indirectly affect OPC differentiation by contributing to increased BBB permeability via secretion of thymidine phosphorylase (TYMP) and vascular endothelial growth factor A (VEGF-A) (Argaw et al., 2012; Chapouly et al., 2015).”
BackgroundA reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713 · cited 1×
“The exact cause of neurodegeneration in MS remains to be seen, however the demonstration that early axonal damage can be reversed with remyelination (Bjartmar et al., 2003; Nikić et al., 2011) strengthens the rationale that pro-remyelination therapies could be beneficial for the treatment of MS.”
BackgroundRejuvenation of Regeneration in the Aging Central Nervous System
Ruckh, J. M., Zhao, J.-W., Shadrach, J. L., van Wijngaarden, P., Rao, T. N., Wagers, A. J., & Franklin, R. J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.11.019 · Cited by 649
Myelination and the trophic support of long axons
Nave, K.-A. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2797 · Cited by 648
Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02451.2002 · Cited by 625
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621 · cited 3×
“Failure to regenerate oligodendrocytes and replace myelin exacerbates axonal dysfunction from myelin loss, leading to a cascade of pathological events that ultimately concludes with neurodegeneration (Trapp and Stys, 2009).”
BackgroundInfluentialHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 2×
“, 1999), their differentiation into re-myelinating cells is halted (Back et al., 2005; Charles et al., 2002, 2000; Fancy et al., 2010; Mi et al., 2005).”
BackgroundBjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573 · cited 1×
“The exact cause of neurodegeneration in MS remains to be seen, however the demonstration that early axonal damage can be reversed with remyelination (Bjartmar et al., 2003; Nikić et al., 2011) strengthens the rationale that pro-remyelination therapies could be beneficial for the treatment of MS.”
BackgroundWolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β-catenin–TCF interaction
Ye, F., Chen, Y., Hoang, T., Montgomery, R. L., Zhao, X.-H., Bu, H., Hu, T., Taketo, M. M., van Es, J. H., Clevers, H., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2333 · Cited by 559 · cited 1×
“Wnt Signaling: Wnt proteins are secreted ligands that play numerous roles in regulating development, including oligodendrocyte genesis (Azim and Butt, 2011; Fancy et al., 2009; Ortega et al., 2013; Shimizu et al., 2005; Ye et al., 2009).”
BackgroundRetinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
Self-citationA regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Interleukin-1β Promotes Repair of the CNS
Mason, J. L., Suzuki, K., Chaplin, D. D., & Matsushima, G. K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07046.2001 · Cited by 502
Rapid Conduction and the Evolution of Giant Axons and Myelinated Fibers
Hartline, D. K., & Colman, D. R. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.042 · Cited by 478 · cited 1×
“This exquisite organization defines the typical vertebrate nerve fiber and is crucial for saltatory propagation of electrical impulses down the axon, enabling rapid communication between networks of nerve cells in the CNS (Bhatt et al., 2014; Frankenhaeuser, 1952; Hartline and Colman, 2007).”
BackgroundMitochondrial changes within axons in multiple sclerosis
Mahad, D. J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P. S., Lassmann, H., & Turnbull, D. M. (2009) · Brain · doi:10.1093/brain/awp046 · Cited by 454
Remyelination protects axons from demyelination-associated axon degeneration
Irvine, K. A., & Blakemore, W. F. (2008) · Brain · doi:10.1093/brain/awn080 · Cited by 420 · cited 3×
“Since remyelination restores axonal conduction and protects against axonal damage in rodent models of MS (Irvine and Blakemore, 2008; Jeffery and Blakemore, 1997; Kornek et al., 2000), it is hypothesized that pro-remyelination therapies may be beneficial for patients with MS.”
BackgroundRemyelination capacity of the MS brain decreases with disease chronicity
Goldschmidt, T., Antel, J., König, F. B., Brück, W., & Kuhlmann, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8260a · Cited by 411 · cited 1×
“Remyelination is remarkably prolific in the early stages of MS (Franklin 2002, Goldschmidt et al., 2009; Patrikios et al., 2006), but becomes less efficient with disease progression for M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT unknown reasons (Goldschmidt et al., 2009; Franklin 2002).”
BackgroundMitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406 · cited 1×
“…(Trapp and Stys, 2009), as abnormalities in mitochondria density, morphology, and activity are consistently found in models of MS (Campbell et al., 2014; Fischer et al., 2012; Joshi et al., 2015; Kiryu-Seo et al., 2010; Mahad et al., 2008, 2009; Qi et al., 2006; Witte et al., 2014, 2010, 2009).”
BackgroundAnimal models of multiple sclerosis: the good, the bad and the bottom line
Ransohoff, R. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3168 · Cited by 379
Function of retinoic acid receptors during embryonic development
Mark, M., Ghyselinck, N. B., & Chambon, P. (2009) · Nuclear Receptor Signaling · doi:10.1621/nrs.07002 · Cited by 363 · cited 1×
“Among them is the nuclear retinoid X receptor (RXR) pathway, which plays an important role in cell proliferation and development (for review see Mark et al., 2009).”
BackgroundMikita, J., Dubourdieu-Cassagno, N., Deloire, M. S., Vekris, A., Biran, M., Raffard, G., Brochet, B., Canron, M.-H., Franconi, J.-M., Boiziau, C., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510379243 · Cited by 358 · cited 3×
“(2011) found that while CAM and AAM are relatively balanced after the first clinical attack following EAE induction, the CAM population significantly outnumbers the AAM population during relapse (Mikita et al., 2011).”
BackgroundResultAxin2 as regulatory and therapeutic target in newborn brain injury and remyelination
Fancy, S. P. J., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini, S. E., Bruce, C. C., Otero, J. J., Huang, E. J., Nusse, R., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2855 · Cited by 349 · cited 3×
“Moreover, mice lacking Axin2, a Wnt target gene that promotes the degradation of β-catenin (Behrens et al., 1998; Jho et al., 2002), exhibit impaired OPC differentiation and delayed remyelination (Fancy et al., 2011b).”
BackgroundKotter, M. R., Zhao, C., van Rooijen, N., & Franklin, R. J. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.019 · Cited by 331
Charles, P., Hernandez, M. P., Stankoff, B., Aigrot, M. S., Colin, C., Rougon, G., Zalc, B., & Lubetzki, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100076197 · Cited by 306 · cited 1×
“While OPCs continue to be recruited to demyelinated regions in approximately 70% of lesions (Chang et al., 2002; Lucchinetti et al., 1999), their differentiation into re-myelinating cells is halted (Back et al., 2005; Charles et al., 2002, 2000; Fancy et al., 2010; Mi et al., 2005).”
BackgroundMi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300 · cited 1×
“Similarly, treatment with a LINGO-1 antagonist results in increased OPC differentiation and enhanced remyelination following EAE and lysolecithin-mediated demyelination (Mi et al., 2009), suggesting that LINGO-1 inhibition may be a useful therapeutic approach.”
BackgroundRemyelination in Experimental Models of Toxin-Induced Demyelination
Blakemore, W. F., & Franklin, R. J. M. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-73677-6_8 · Cited by 275
Ortega, F., Gascón, S., Masserdotti, G., Deshpande, A., Simon, C., Fischer, J., Dimou, L., Chichung Lie, D., Schroeder, T., & Berninger, B. (2013) · Nature Cell Biology · doi:10.1038/ncb2736 · Cited by 247 · cited 2×
“Wnt Signaling: Wnt proteins are secreted ligands that play numerous roles in regulating development, including oligodendrocyte genesis (Azim and Butt, 2011; Fancy et al., 2009; Ortega et al., 2013; Shimizu et al., 2005; Ye et al., 2009).”
BackgroundInterleukin-1 Regulates Proliferation and Differentiation of Oligodendrocyte Progenitor Cells
Vela, J. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1127 · Cited by 223 · cited 2×
“, 2001; Ousman and David, 2000; Robinson and Miller, 1999), or by secreting pro-remyelination cytokines and growth factors (Arnett et al., 2001; Hinks and Franklin, 1999; Kotter et al., 2005; Mason et al., 2001; Vela et al., 2002).”
BackgroundNotch1 control of oligodendrocyte differentiation in the spinal cord
Genoud, S., Lappe-Siefke, C., Goebbels, S., Radtke, F., Aguet, M., Scherer, S. S., Suter, U., Nave, K.-A., & Mantei, N. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202002 · Cited by 211
Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination
Zhang, Y., Argaw, A. T., Gurfein, B. T., Zameer, A., Snyder, B. J., Ge, C., Lu, Q. R., Rowitch, D. H., Raine, C. S., Brosnan, C. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902834106 · Cited by 210 · cited 5×
“Genetic inactivation of Notch1 in OPCs produces a similar phenotype characterized by premature OPC differentiation (Zhang et al., 2009).”
BackgroundResultInfluentialAstrocyte-derived endothelin-1 inhibits remyelination through notch activation
Hammond, T. R., Gadea, A., Dupree, J., Kerninon, C., Nait-Oumesmar, B., Aguirre, A., & Gallo, V. (2014) · Neuron · doi:10.1016/j.neuron.2013.11.015 · Cited by 206
Semaphorin signalling during development
Jongbloets, B. C., & Pasterkamp, R. J. (2014) · Development · doi:10.1242/dev.105544 · Cited by 205 · cited 1×
“Semaphorins regulate neural development primarily by forming migratory cues through extracellular matrix binding to plexin and neuropillin receptors (for review see Jongbloets and Pasterkamp, 2014).”
BackgroundEfficient central nervous system remyelination requires T cells
Bieber, A. J., Kerr, S., & Rodriguez, M. (2003) · Annals of Neurology · doi:10.1002/ana.10578 · Cited by 196 · cited 2×
“…and demyelination, depletion of immune cells including macrophages, microglia, and T cells or removal of pro-inflammatory factors including TNFα, IL-1β, and MHCII paradoxically impairs the remyelination process (Arnett et al., 2001; Bieber et al., 2003; Kotter et al., 2005; Mason et al., 2001).”
BackgroundMechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191 · cited 1×
“In the context of MS, this leads to widespread primary demyelination by promoting the phagocytosis of myelin fragments and dying oligodendrocytes by macrophages/microglia and reactive astrocytes (Lassmann, 2014; Sosa et al., 2013; Wu and Raine, 1992).”
BackgroundOntogeny and Functions of Central Nervous System Macrophages
Katsumoto, A., Lu, H., Miranda, A. S., & Ransohoff, R. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400716 · Cited by 149 · cited 1×
“It is important to note that the distinction between CAM and AAM is not always clear, as microglia and macrophages are plastic and respond rapidly to changes in their environment and can acquire a diverse range of activation programs depending on the stimuli received (Katsumoto et al., 2014).”
BackgroundInhibition of CNS Remyelination by the Presence of Semaphorin 3A
Syed, Y. A., Hand, E., Möbius, W., Zhao, C., Hofer, M., Nave, K. A., & Kotter, M. R. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4930-10.2011 · Cited by 134 · cited 3×
“In contrast, another study found that SEMA3A directly inhibits OPC differentiation in vitro (Syed et al., 2011).”
BackgroundResultTraka, M., Arasi, K., Avila, R. L., Podojil, J. R., Christakos, A., Miller, S. D., Soliven, B., & Popko, B. (2010) · Brain · doi:10.1093/brain/awq247 · Cited by 118 · cited 3×
“Moreover, targeted ablation of oligodendrocytes in mice resulted in axonal pathology (Oluich et al., 2012; Traka et al., 2010).”
BackgroundExperimental models of multiple sclerosis
Pachner, A. R. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328346c226 · Cited by 90 · cited 11×
“M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT”
BackgroundInfluentialYuen, T. J., Johnson, K. R., Miron, V. E., Zhao, C., Quandt, J., Harrisingh, M. C., Swire, M., Williams, A., McFarland, H. F., Franklin, R. J. M., et al. (2013) · Brain · doi:10.1093/brain/awt024 · Cited by 80 · cited 1×
“ET-2 is also implicated in the regulation of CNS remyelination, as it has been shown to promote OPC differentiation and remyelination in a model of innate immunity (Yuen et al., 2013).”
BackgroundUpdate on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55 · cited 2×
“Notably, although current immunosuppressive therapies reduce the number of relapses, they do not prevent patients from progressing (Carrithers, 2014; Rice CM, 2014) or developing significant cortical atrophy (Sailer et al., 2003).”
Background
Cited by
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Pentón-Rol, G., Marín-Prida, J., & Falcón-Cama, V. (2018) · Behavioral Sciences · doi:10.3390/bs8010015 · Cited by 50
“Even in OPCs that differentiate, contact and enwrap axons, the final maturation into compact myelin may be interrupted [36].”
BackgroundExosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis
Ojeda-Hernández, D. D., Hernández-Sapiéns, M. A., Reza-Zaldívar, E. E., Canales-Aguirre, A., Matías-Guiu, J. A., Matías-Guiu, J., Mateos-Díaz, J. C., Gómez-Pinedo, U., & Sancho-Bielsa, F. (2022) · Life · doi:10.3390/life12091417 · Cited by 25
“On the other hand, the use of chemoattractants to improve the remyelination process is being investigated [34,35].”
BackgroundScalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Metadata
- Authors
- Chamberlain, K. A., Nanescu, S. E., Psachoulia, K., & Huang, J. K.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 110
- Issue
- Pt B
- Pages
- 633-643
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2176522607
- Cited by
- 87
- References
- 61
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.